Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

ance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the immunologic activity of HspE7 in treating CIN; that we identified an optimal dosing range for Phase 2 development and that our TLR3 agonist may have application in both therapeutic as well as prophylactic vaccines.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that immunologic activity of HspE7 may not treat CIN; the possibility that immunology responses may not be a predictor of clinical or therapeutic benefit; our need for capital; the outcomes of our clinical trials; the possibility that our drug candidate will not treat target diseases as intended; the possibility that we will not be successful in licensing our TLR3 agonist to other vaccine developers; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at '/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 While administrative claims and ... research for a relatively long period of time, ... the use of these ‘big data’ for comparisons ... combining today’s powerful computer technology with the plethora ... data’ holds significant promise for identifying optimal interventions ...
(Date:7/30/2014)... SEGUNDO, Calif. , July 30, 2014 /PRNewswire/ ... contractor on the Fully Integrated Lifecycle Mission Support ... and Space Administration (NASA). Under the terms of ... Ames Research Center at Moffett Field, Calif. In ... support for bioscience flight development projects on the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 BCC Research ... Global Markets for Enzymes in Industrial Applications , the ... to nearly $7.1 billion by 2018, registering a five-year ... is estimated to be recorded in the detergent enzyme ... period. , Enzyme technology has influenced almost every sector ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... HILL, N.J., Jan. 7 TriMix Laboratories LLC today,announced ... alternative for patients who fail on Viagra(R) type pills,and ... With twenty million,American men currently suffering with ED, current ... and more men who can,t tolerate the,side effects of ...
... Discovery Inc., a privately held,biopharmaceutical company developing genetically ... today announced Richard B.,Brewer, President and Chief Executive ... Conference on Tuesday, January 8 at 2:00 PM ... held January 7-10, 2008 at,the Westin St. Francis ...
... Jan. 4 Burrill & Company is pleased to,announce the following ... Director -- Bryant joined Burrill in 1998 ... molecular biologist. Bryant, a UC Berkeley graduate ... Cell Biology-Biochemistry, has served the Venture arm ...
Cached Biology Technology:Difficult to Treat Erectile Dysfunction Patients 2Difficult to Treat Erectile Dysfunction Patients 3ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008 2
(Date:7/30/2014)... a massive collection of 20-million-year-old amber found in the ... effort is yielding fresh insights into ancient tropical insects ... is fully curated, a task that will take many ... collection in the world, the researchers report. , ... of a pygmy locust, a tiny grasshopper the size ...
(Date:7/30/2014)... Monash University Professor Steven Chown has been awarded ... Medal for Excellence in Antarctic Research. , SCAR, ... coordinates high quality international scientific research in the ... Antarctic region in the Earth system. The organisation ... Antarctic Treaty System, responsible for governing the region. ...
(Date:7/30/2014)... Progress in developing robust therapies for spinal cord injury ... has been slow. A great deal has been learned ... factors and the environmental factors that regulate axon growth, ... resulted in clinically available therapeutics. Prof. Lemmon and his ... therapeutic bottleneck has many root causes, but a consensus ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2
... Despite research efforts to find modern factors that would ... the gap is actually ancient and universal, according to ... almost every country, and the sex difference in lifespan ... said Daniel J. Kruger, a research scientist in the ...
... small, inexpensive remote-control plane as a sensing tool, also known ... team plans to test it over the Konza Prairie Biological ... performs as the team hopes, it will be made available ... it to obtain high-resolution images and reliable data. , The ...
... has been developed, which quite literally sucks the life ... place ozone-depleting chemicals, like methyl bromide, which are currently ... called metabolic stress disinfection (MSDD), was developed by Manuel ... (Journal of the Science of Food and Agriculture DOI ...
Cached Biology News:Evolutionary forces explain why women live longer than men 2K-Staters design and build a low-cost remote sensing tool for environmental studies 2K-Staters design and build a low-cost remote sensing tool for environmental studies 3
... standard BioLogic LP system, 220-240 V, ... without fraction collection. The system includes ... accessory kit with MV-6 injection valve, ... conductivity cell, tubing and fittings kit, ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... system with colony-picking capabilities, 110-120 V, uses ... proteins, oligonucleotides, carbohydrates, lipids, and other biomolecules ... applications. This system can also be used ... micrometers in diameter and for inoculating 96- ...
The SmartSpec printer paper is used to record data generated by the SmartSpec Plus spectrophotometer. Supplied as 5 packs....
Biology Products: